HeartSciences Inc.

Name: HeartSciences Inc. standardized financial statements, quarterly
Creator: Listed

HSCSNasdaqCIK 1468492FinancialsFiscal year ends Apr 30

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$2.1k, Q1 FY2027

Operating income−$2.9m, Q1 FY2027

Net income−$3.2m, Q1 FY2027

HeartSciences Inc., income statement, quarterly
Line item	Unit	Q2 FY20242023-10-31	Q3 FY20242024-01-31	Q4 FY20242024-04-30	Q1 FY20252024-07-31	Q2 FY20252024-10-31	Q3 FY20252025-01-31	Q4 FY20252025-04-30	Q1 FY20262025-07-31	Q2 FY20262025-10-31	Q3 FY20262026-01-31	Q4 FY20262026-04-30	Q1 FY20272026-07-31
Revenue	$k	3.9	14.7	0.0	not reported	not reported	0.0	4.4	1.9	2.4	0.0	0.0	2.1
Cost of revenue	$k	1.5	4.6	0.0	not reported	not reported	0.0	1.9	0.8	1.0	0.0	0.0	0.8
Gross profit	$k	2.4	10.1	0.0	not reported	not reported	0.0	2.5	1.1	1.4	0.0	0.0	1.3
Research and development	$k	757	510	1,046	1,225	1,199	1,033	929	997	727	639	476	907
Selling, general and administrative	$k	815	1,026	834	851	786	1,338	994	878	1,348	1,290	2,060	2,034
Operating income	$k	(1,570)	(1,525)	(1,880)	(2,076)	(1,985)	(2,371)	(1,920)	(1,874)	(2,073)	(1,929)	(2,536)	(2,939)
Interest expense	$k	178	118	20.9	22.5	118	179	181	184	280	61.5	228	235
Net income	$k	(1,748)	(1,644)	(1,846)	(2,052)	(2,083)	(2,536)	(2,094)	(2,055)	(2,351)	(1,985)	(2,751)	(3,172)
Diluted EPS	$ per share	(15.92)	(3.01)	not reported	(2.64)	(2.27)	(2.57)	not reported	(1.58)	(0.85)	not reported	not reported	not reported
Basic EPS	$ per share	(15.92)	(3.01)	not reported	(2.64)	(2.27)	(2.57)	not reported	(1.58)	(0.85)	(0.63)	not reported	(0.86)

Balance sheet

Cash and equivalents$29.9k, Q1 FY2027

Shareholders' equity−$2.0m, Q1 FY2027

HeartSciences Inc., balance sheet, quarterly
Line item	Unit	FY20242024-04-30	Q1 FY20252024-07-31	Q2 FY20252024-10-31	Q3 FY20252025-01-31	FY20252025-04-30	Q1 FY20262025-07-31	Q2 FY20262025-10-31	period not labelled2025-12-31	Q3 FY20262026-01-31	FY20262026-04-30	period not labelled2026-06-30	Q1 FY20272026-07-31
Cash and equivalents	$k	5,808	4,340	4,052	2,597	1,100	2,792	1,951	1,098	3,397	1,657	1,657	29.9
Current assets	$k	7,354	6,075	5,689	3,629	2,171	4,417	3,793	2,171	5,099	2,583	2,583	812
Total assets	$k	9,503	8,191	7,777	5,704	4,223	6,437	5,996	4,223	7,555	5,263	5,263	3,737
Current liabilities	$k	1,752	1,352	3,303	3,571	3,703	3,015	1,566	3,703	4,269	4,861	4,861	5,633
Total liabilities	$k	2,186	2,257	3,761	3,917	4,018	3,296	1,814	4,018	4,902	5,037	5,037	5,770
Shareholders' equity	$k	7,317	5,934	4,017	1,787	205	3,141	4,182	205	2,652	226	226	(2,033)

Cash flow

Operating cash flow−$1.3m, Q1 FY2027

Capital expenditure$0, Q4 FY2026

HeartSciences Inc., cash flow, quarterly
Line item	Unit	Q2 FY20242023-10-31	Q3 FY20242024-01-31	Q4 FY20242024-04-30	Q1 FY20252024-07-31	Q2 FY20252024-10-31	Q3 FY20252025-01-31	Q4 FY20252025-04-30	Q1 FY20262025-07-31	Q2 FY20262025-10-31	Q3 FY20262026-01-31	Q4 FY20262026-04-30	Q1 FY20272026-07-31
Operating cash flow	$k	(988)	(2,101)	(1,577)	(2,019)	(2,184)	(1,620)	(1,591)	(1,953)	(2,334)	(1,463)	(1,677)	(1,319)
Capital expenditure	$k	2.0	8.8	48.8	not reported	not reported	0.0	0.0	not reported	not reported	(9.5)	0.0	not reported

Diluted shares (weighted)2.78m, Q2 FY2026

HeartSciences Inc., shares, quarterly
Line item	Unit	period not labelled2022-01-31	Q1 FY20232022-07-31	Q2 FY20232022-10-31	Q3 FY20232023-01-31	Q1 FY20242023-07-31	Q2 FY20242023-10-31	Q3 FY20242024-01-31	Q1 FY20252024-07-31	Q2 FY20252024-10-31	Q3 FY20252025-01-31	Q1 FY20262025-07-31	Q2 FY20262025-10-31
Diluted shares (weighted)	k shares	3,324	5,645	8,210	8,241	103	110	547	778	917	986	1,304	2,780

Shares outstanding: 4.80m at Sep 11, 2026, from the cover of the 10-Q filed Sep 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. Listed shows no prices and gives no investment advice.